Medullary thyroid cancer: An update of new guidelines and recent developments

Current Opinion in Oncology

Volumn 23, Issue 1, 2011, Pages 22-27

  Wu, Leslie S ^a   Roman, Sanziana A ^b   Sosa, Julie A ^b  

^a MAINE MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcitonin and carcinoembryonic antigen screening; Medullary thyroid cancer; Neck dissection; Novel chemotherapy; Thyroidectomy

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; MOTESANIB; PLACEBO; PROCALCITONIN; PROTEIN RET; SORAFENIB; SUNITINIB; VANDETANIB; XL 184;

ARTICLE; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FAMILIAL CANCER; FAMILIAL MEDULLARY THYROID CANCER; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MULTIPLE ENDOCRINE NEOPLASIA 2A; MULTIPLE ENDOCRINE NEOPLASIA 2B; OVERALL SURVIVAL; PHEOCHROMOCYTOMA; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; UNSPECIFIED SIDE EFFECT;

CARCINOMA, MEDULLARY; HUMANS; PRACTICE GUIDELINES AS TOPIC; THYROID NEOPLASMS;

EID: 79851513758     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328340b527     Document Type: Article

References (42)

1. Hazard JB, Crile G Jr. Medullary (solid) carcinoma of the thyroid: a clinico- pathologic entity. J Clin Endocrinol Metab 1959; 19:152-161.
2. Dralle J, Machens A. Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab 2008; 22:971-987.
3. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88:1139-1148. (Pubitemid 30127676)
4. Machens A, Schneyer U, Holzhausen HJ, et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005; 90:2029-2034. (Pubitemid 40586235)
5. Moley J. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Comprehensive Cancer Network 2010; 8:549-556.
6. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
7. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565-612.
8. British Thyroid Association. Guidelines for the management of thyroid cancer; 2007. http://www.british-thyroid-association.org/Guidelines/. [Accessed July 2010]
9. Al-Rawi M, Wheeler MH. Medullary thyroid carcinoma: update and present management controversies. Ann Roy Coll Surg Engl 2006; 88:433-438. (Pubitemid 44390349)
10. Gharib H, Papini E, Valcavi R, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologic medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocrine Pract 2006; 12:63-102.
11. American Head and Neck Society. Guidelines for medullary thyroid carcinoma; 1995. http://www.ahns.info/clinicalresources/guidelines.php. [Accessed July 2010]
12. National Comprehensive Cancer Network. Clinical practice guidelines for medullary thyroid carcinoma; 2010. http://www.nccn.org/professionals/phy-sician- gls/f-guidelines.asp. [Accessed July 2010]
13. Panigrahi B, Roman SA, Sosa JA. Medullary thyroid cancer: are practice patterns in the United States discordant from American Thyroid Association guidelines? Ann Surg Oncol 2010; 17:1490-1498.
14. Pitman MB, Oertel YC, Geisinger KR. Medullary thyroid carcinoma. In: Ali SZ, Cibas ES, editors. The Bethesda system for reporting thyroid cytopathology. 1st ed. New York City: Springer Science/Business Media; 2010. pp. 117 -128.
15. Elisei R, Cosci B, Romei C, et al Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008; 93:682-687. (Pubitemid 351398539)
16. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003; 349:1517-1525. (Pubitemid 37255037)
17. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist 2008; 13:539-547. (Pubitemid 351872871)
18. Machens A, Ukkat J, Brauckhoff M, et al. Advances in the management of hereditary medullary thyroid cancer. J Internal Med 2005; 257:50-59. (Pubitemid 40129126)
19. Castellone MD, Santoro M. Dysregulated RET signaling in thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:363-374. (Pubitemid 351698089)
20. Roman S, Mehta P, Sosa JA. Medullary thyroid cancer: early detection and novel treatments. Curr Opin Oncol 2008; 21:5-10.
21. Zenaty D, Aigrain Y, Peuchmaur M, et al. Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. Eur J Endocrinol 2009; 160:807-813.
22. Howe JR, Norton JA, Wells SJ. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 1993; 114:1070-1077. (Pubitemid 24004725)
23. Hyer SL, Vini L, A'Hern R, Harmer C. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 2000; 26:686-690.
24. Moo-Young TA, TraugottAL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am 2009; 89:1193-1204.
25. Giraudet AL, Al Ghulzan A, Auperin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008; 158:239-246. (Pubitemid 351298542)
26. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2655-2663.
27. Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007; 92:4185-4190. (Pubitemid 350074730)
28. Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007; 33:493-497. (Pubitemid 46586095)
29. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol 1998; 48:265-273. (Pubitemid 28137636)
30. Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003; 88:2070-2075. (Pubitemid 36549878)
31. Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001; 130:1044-1049. (Pubitemid 34014572)
32. Faggiano A, Milone F, Ramundo V, et al. A decrease of calcitonin serum concentrations of less than 50% at 30 min after thyroid surgery suggests incomplete C-cell tumor tissue removal. J Clin Endocrinol Metab 2010. [Epub ahead of print]
33. Boostrom SY, Grant CS, Thompson GB, et al. Need for a revised staging consensus in medullary thyroid carcinoma. Arch Surg 2009; 144:663-669.
34. Meijer JAA, le Cessie S, van den Hout WB, et al. Calcitonin and carcinoem-bryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol 2010; 72:534-542.
35. Algeciras-Schimnich A, Preissner CM, Theobald JP, et al. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2009; 94:861-868.
36. Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 2008; 32:754-765.
37. Dackiw APB. The surgical management of medullary thyroid cancer. Otolaryngol Clin North Am 2010; 43:365-374.
38. Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6:305-310. (Pubitemid 26303135)
39. Kraeber-Bodere F, Goldenberg DM, Chatal JF, Barbet J. Pretargeted radio- immunotherapy in the treatment of metastatic medullary thyroid cancer. Curr Oncol 2009; 16:3-8.
40. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009; 94:1493-1499.
41. Kurzrock R, Cohen EE, Sherman D, et al. Long-term results in a cohort of medullary thyroid cancer patients in a phase I study ofSL184, an oral inhibitor of MET, VEGFR2, and RET. J Clin Oncol 2010; 28 (Suppl 15):abstract 5502.
42. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28:767-772.